286 related articles for article (PubMed ID: 21114387)
21. Candidemia in children.
Zaoutis T
Curr Med Res Opin; 2010 Jul; 26(7):1761-8. PubMed ID: 20513207
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
23. Echinocandins vs. amphotericin B against invasive candidiasis in children and neonates: A meta-analysis of randomized controlled trials.
Chen YH; Cheng IL; Lai CC; Tang HJ
Int J Antimicrob Agents; 2019 Jun; 53(6):789-794. PubMed ID: 30831231
[TBL] [Abstract][Full Text] [Related]
24. Editorial commentary: Is the debate about treatment of Candida parapsilosis complex infections with echinocandins much ado about nothing?
Reboli AC
Clin Infect Dis; 2014 May; 58(10):1422-3. PubMed ID: 24642556
[No Abstract] [Full Text] [Related]
25. Caspofungin therapy in immunocompromised children and neonates.
Somer A; Törün SH; Salman N
Expert Rev Anti Infect Ther; 2011 Mar; 9(3):347-55. PubMed ID: 21417874
[TBL] [Abstract][Full Text] [Related]
26. Anidulafungin for the treatment of invasive candidiasis.
Mayr A; Aigner M; Lass-Flörl C
Clin Microbiol Infect; 2011 Mar; 17 Suppl 1():1-12. PubMed ID: 21251147
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis.
Tsekoura M; Ioannidou M; Pana ZD; Haidich AB; Antachopoulos C; Iosifidis E; Kolios G; Roilides E
Pediatr Infect Dis J; 2019 Jan; 38(1):42-49. PubMed ID: 29596219
[TBL] [Abstract][Full Text] [Related]
28. Breakthrough candidemia in children: clinical and microbiological characteristics, therapeutic strategies and impact on outcomes.
Lai MY; Hsu JF; Chu SM; Wu IH; Huang HR; Lin CC; Lee IT; Chiang MC; Fu RH; Tsai MH
Future Microbiol; 2017 Jun; 12():695-705. PubMed ID: 28326813
[TBL] [Abstract][Full Text] [Related]
29. Early clinical experience with anidulafungin at a large tertiary care medical center.
Brielmaier BD; Casabar E; Kurtzeborn CM; McKinnon PS; Ritchie DJ
Pharmacotherapy; 2008 Jan; 28(1):64-73. PubMed ID: 18154476
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant.
Natale F; Castronovo A; Regoli D; De Curtis M; Manzoni P
Pediatr Infect Dis J; 2009 May; 28(5):452. PubMed ID: 19295457
[No Abstract] [Full Text] [Related]
31. Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections.
Holt SL; Drew RH
Am J Health Syst Pharm; 2011 Jul; 68(13):1207-20. PubMed ID: 21690427
[TBL] [Abstract][Full Text] [Related]
32. Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis.
Keane S; Geoghegan P; Povoa P; Nseir S; Rodriguez A; Martin-Loeches I
Expert Rev Anti Infect Ther; 2018 Nov; 16(11):839-847. PubMed ID: 30257597
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.
Undre NA; Stevenson P; Freire A; Arrieta A
Pediatr Infect Dis J; 2012 Jun; 31(6):630-2. PubMed ID: 22301478
[TBL] [Abstract][Full Text] [Related]
34. [Development of Candida parapsilosis candidemia during caspofungin therapy].
Gutiérrez Urbón JM; Galeiras Vázquez R; Velasco Fernández D; Alvarez Rocha L
Farm Hosp; 2011; 35(5):282-5. PubMed ID: 21705252
[No Abstract] [Full Text] [Related]
35. [Relationship between the effectiveness and dose of micafungin in the treatment of candidemia].
Sugawara T; Murakami N; Uetake N; Matsumoto S; Miyamori S; Okamoto R; Hiraki K
Yakugaku Zasshi; 2014; 134(3):433-8. PubMed ID: 24584025
[TBL] [Abstract][Full Text] [Related]
36. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.
Andes DR; Safdar N; Baddley JW; Playford G; Reboli AC; Rex JH; Sobel JD; Pappas PG; Kullberg BJ;
Clin Infect Dis; 2012 Apr; 54(8):1110-22. PubMed ID: 22412055
[TBL] [Abstract][Full Text] [Related]
37. Our 2014 approach to candidaemia.
Koehler P; Tacke D; Cornely OA
Mycoses; 2014 Oct; 57(10):581-3. PubMed ID: 24863378
[TBL] [Abstract][Full Text] [Related]
38. Echinocandins in invasive candidiasis.
Simon J; Sun HY; Leong HN; Barez MY; Huang PY; Talwar D; Wang JH; Mansor M; Wahjuprajitno B; Patel A; Wittayachanyapong S; Sany BS; Lin SF; Dimopoulos G
Mycoses; 2013 Nov; 56(6):601-9. PubMed ID: 23647521
[TBL] [Abstract][Full Text] [Related]
39. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.
Kett DH; Shorr AF; Reboli AC; Reisman AL; Biswas P; Schlamm HT
Crit Care; 2011; 15(5):R253. PubMed ID: 22026929
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer.
Farmakiotis D; Tarrand JJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Jun; 58(6):3526-9. PubMed ID: 24637687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
